Advertisement
Screener

Palvella Therapeutics, Inc. (PVLA) Other Revenue, Net (Deprecated 2018-01-31)

2.5 / 5 stars · 40/81 Roast Me

Palvella Therapeutics, Inc. Other Revenue, Net (Deprecated 2018-01-31)

Palvella Therapeutics, Inc. (PVLA) reported Other Revenue, Net (Deprecated 2018-01-31) of $91.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-18.

Discontinued › Income Statement › Other Income

us-gaap:OtherSalesRevenueNet · last filed 2019-03-18

  • Palvella Therapeutics, Inc. other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-12-31 was $0.00.
  • Palvella Therapeutics, Inc. other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
  • Palvella Therapeutics, Inc. other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $0.00.
  • Palvella Therapeutics, Inc. other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $91.00K.
  • Palvella Therapeutics, Inc. other revenue, net (deprecated 2018-01-31) for fiscal 2018 was $91.00K, a 550.00% increase from fiscal 2017.
  • Palvella Therapeutics, Inc. other revenue, net (deprecated 2018-01-31) for fiscal 2017 was $14.00K.
  • Palvella Therapeutics, Inc. other revenue, net (deprecated 2018-01-31) for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
  • Palvella Therapeutics, Inc. other revenue, net (deprecated 2018-01-31) for fiscal 2015 was $18.44K.
Period endOther Revenue, Net (Deprecated 2018-01-31) 3 monthOther Revenue, Net (Deprecated 2018-01-31) 6 monthOther Revenue, Net (Deprecated 2018-01-31) 9 monthOther Revenue, Net (Deprecated 2018-01-31) 12 month
2018-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18
$0.00
derived: sum of 2 quarters · filed 2019-03-18
$0.00
derived: sum of 3 quarters · filed 2019-03-18
$91.00K
10-K · filed 2019-03-18
2018-09-30$0.00
10-Q · filed 2018-11-07
$0.00
derived: sum of 2 quarters · filed 2018-11-07
$91.00K
10-Q · filed 2018-11-07
$91.00K
derived: sum of 4 quarters · filed 2019-03-18
2018-06-30$0.00
10-Q · filed 2018-08-09
$91.00K
10-Q · filed 2018-08-09
$91.00K
derived: sum of 3 quarters · filed 2019-03-18
$105.00K
derived: sum of 4 quarters · filed 2019-03-18
2018-03-31$91.00K
10-Q · filed 2018-05-10
$91.00K
derived: sum of 2 quarters · filed 2019-03-18
$105.00K
derived: sum of 3 quarters · filed 2019-03-18
$105.00K
derived: sum of 4 quarters · filed 2019-03-18
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18
$14.00K
derived: sum of 2 quarters · filed 2019-03-18
$14.00K
derived: sum of 3 quarters · filed 2019-03-18
$14.00K
10-K · filed 2019-03-18
2017-09-30$14.00K
10-Q · filed 2018-11-07
$14.00K
derived: sum of 2 quarters · filed 2018-11-07
$14.00K
10-Q · filed 2018-11-07
2017-06-30$0.00
10-Q · filed 2018-08-09
$0.00
10-Q · filed 2018-08-09
2017-03-31$0.00
10-Q · filed 2018-05-10
2016-12-31$0.00
10-K · filed 2018-03-15
2015-12-31$18.44K
10-K · filed 2017-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Generate Biomedicines, Inc. (GENB)United States$2.052B
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12